Form 4: Guardant Health Director Steve Krognes Receives Equity Compensation

Guardant Health, Inc. Director Steve E. Krognes was granted 6,833 stock options and 4,203 restricted stock units (RSUs) as part of his compensation.

Summary

• Steve E. Krognes, a Director at Guardant Health, Inc. (GH), was granted equity compensation on June 18, 2025.
• The compensation includes 6,833 stock options with an exercise price of $50.57 per share, expiring on June 18, 2035.
• Additionally, Mr. Krognes received 4,203 Restricted Stock Units (RSUs).
• Both the stock options and RSUs are scheduled to vest in full on the one-year anniversary of the grant date (June 18, 2025) or the date of the next annual stockholders meeting, whichever occurs earlier.

Sentiment

Score: 5

Explanation: The document reports a routine equity compensation grant to a director, which is a neutral event in terms of immediate company performance or outlook. It reflects standard corporate governance practices.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Future Outlook

The document primarily details an equity grant and its vesting schedule, indicating that the stock options and restricted stock units are expected to vest in full on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier. No broader forward-looking statements regarding company performance or financial guidance are provided.

Industry Context

The grant of equity compensation, including stock options and restricted stock units, to directors is a common and established practice across various industries, particularly in the biotechnology and healthcare sectors where Guardant Health operates. This method of compensation is widely used to align the interests of board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The provision of equity compensation (stock options and RSUs) to non-employee directors is a standard practice in corporate governance across the U.S. market, particularly within the life sciences and technology sectors.
• While specific comparable companies or projects are not detailed in this filing, the structure of the grant (vesting over one year or until the next annual meeting) is typical for director compensation, aiming to incentivize continued service and alignment with shareholder value.

Related Party Transactions

• The grant of 6,833 stock options and 4,203 restricted stock units to Steve E. Krognes, a Director of Guardant Health, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value, potentially leading to more aligned decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options and restricted stock units are scheduled to vest in full on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Stock Option, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Executive Compensation